• Number of Adverse Events [ Time Frame: up to 4 weeks post procedure. ] [ Designated as safety issue: Yes ]
  Safety of the procedure will be assessed by incidence and severity of intra and post procedure related adverse events (AEs)
  
  

• Hysteroscopic Cryoablation Related Pain Will be Measured by Self Reported Pain Severity Visual Analogue Scale (VAS) Completed by the Patient [ Time Frame: Prior to hospital discharge (less than 24 hours post-procedure) ] [ Designated as safety issue: No ]
  Hysteroscopic cryoablation related pain will be measured by self reported pain severity Visual Analogue Scale (VAS) from a scale of 1 (no pain) to 10 (very severe pain) completed by the patient
  
  
• Time (in Days) to Return to Normal Activity [ Time Frame: 4 weeks post procedure ] [ Designated as safety issue: No ]
  The number of days needed to return to normal activity was assessed by the participant and reported to the investigator. The response was documented at follow-up.
  
  
• Number of Participants Discharged on Day of Cryoablation Procedure. [ Time Frame: Post procedure ] [ Designated as safety issue: No ]
  Per the protocol, this outcome intended to report the average duration of post operative hospital stay. However, this measurement was made very generally and was not collected in number of hours, only the dates were collected. The only actual data that can be stated is that all subjects were discharged from the hospital on the same day as the procedure. In order to report the average length of hospital stay, the wording on the outcome measure title has been changed.
  
  
• Evaluation of Length of an Average Cryoablation Procedure [ Time Frame: Post procedure ] [ Designated as safety issue: No ]
  Evaluation of length of an average cryoablation procedure for the treatment of uterine fibroids
  
  
• Physician's Satisfaction From the Ease and Convenience of the Cryoablation Procedure [ Time Frame: Post procedure ] [ Designated as safety issue: No ]
  Physician's satisfaction from the ease and convenience of the cryoablation procedure using a scale of 1 (very satisfied) to 5 (very dissatisfied).
  
  

Currently there are no optimal methods for treating symptomatic uterine fibroids. Existing therapeutic options are conservative (medications), invasive (e.g., hysterectomy, surgical myomectomy), or minimally invasive (uterine artery embolization, or myolysis).

Fibroid ablation using cryogenic energy, known as Cryoablation, offers a potential alternative method of fibroid treatment. Cryotherapy is a well-established technique for the treatment of various benign and malignant conditions. Cryoablation has been described for the treatment of prostate cancer, renal cell carcinoma, liver tumors and benign and malignant breast tumors.

Galil Medical's proposed feasibility study is looking to examine the technical success, safety and feasibility of a hysteroscopic approach for the treatment of symptomatic fibroids. This technique involves the insertion and placement of Galil Medical's 17-gauge cryoablation needle(s)guided by a hysteroscopic device. Ultrasound provides real-time monitoring of the needle insertion, placement and iceball propagation during the cryoablation procedure.

This treatment offers the patient to preserve her uterus by a minimally invasive procedure. The type of the fibroids intended for treatment (Type II submucous myomas)are often very difficult to completely and safely remove hysteroscopically and are often treated through an open or laparoscopic procedure. A hysteroscopic procedure does not involve intraperitoneal intervention and is therefore expected to be associated with less intra-operative and post-operative complications.

The recovery from hysteroscopic cryoablation is expected to be fast with only minimal self resolving discomfort. The patient should be able to return to her normal activity within 24-48 hours.